If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Substantial Shareholding

11 Jul 2008 10:51

RNS Number : 8759Y
ReGen Therapeutics PLC
11 July 2008
 



11th July 2008

REGEN THERAPEUTICS PLC 

("ReGen" or the "Company"; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

 

2. Reason for the notification:

An acquisition or disposal of voting rights

 

3. Full name of person(s) subject to the notification obligation (iii):

Andrew Clement Wilson

 

4. Full name of shareholder(s) (if difference from 3):

As above

 

5. Date of the transaction and date on which the threshold is crossed or reached (v):

9 July 2008

 

6. Date on which issued notified:

10 July 2008

 

7. Threshold(s) that is/are crossed or reached:

14

 

8. Notified details 

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code GB00B28XMY25

Situation Previous to the triggering transaction (vi) -

Number of Shares 1,490,000

Number of Voting Rights (viii) 1,490,000

Resulting situation after the triggering transaction (viii) -

Number of Shares 1,616,000

Number of Voting Rights - Direct (x) 1,616,000

Number of Voting Rights - Indirect (xi) N/A

% of voting rights - Direct 14.07%

% of voting rights - Indirect N/A

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument N/A

Expiration date (xiii) N/A

Exercise/Conversion Period/Date (xiv) N/A

Number of voting rights that may be acquired if the 

instrument is exercised/converted N/A

% of voting rights N/A

Total (A+B)

Number of voting rights 1,616,000

% of voting rights 14.07

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

Shares are held in own name

Proxy Voting:

 

10. Name of the proxy holder: N/A

 

11. Number of voting rights proxy holder will cease to hold: N/A

 

12. Date on which proxy holder will cease to hold voting rights: N/A

 

13. Additional information: N/A

 

14. Contact name: N/A

 

15. Contact telephone number: N/A

For further information:

 

Percy Lomax

ReGen Therapeutics Plc

Tel: +44 (0) 207 153 4920

Roland Cornish / Felicity Geidt

Beaumont Cornish Limited

Tel:  +44(0) 207 628 3396

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFKDKQCBKKCOD
Date   Source Headline
8th Apr 20097:00 amRNSIssue of Equity
31st Mar 200910:49 amRNSTotal Voting Rights
26th Mar 20095:38 pmRNSNotification of Major Interest in Shares
26th Mar 200912:49 pmRNSResults of General Meeting
25th Mar 20099:30 amRNSNotification of Major Interest in Shares
25th Mar 20097:00 amRNSDistribution Agreement and Issue of Equity
25th Mar 20097:00 amRNSManufacturing Agreement
12th Mar 20097:00 amRNSFirst stage peptide studies
4th Mar 20094:07 pmRNSHolding(s) in Company
2nd Mar 20097:00 amRNSEGM Circular
27th Feb 20093:09 pmRNSTotal Voting Rights
26th Feb 20097:00 amRNSHoldings in Company
19th Feb 20097:00 amRNSFurther issue of shares
18th Feb 20097:00 amRNSIssue of Equity and Shareholdings
30th Jan 200912:53 pmRNSTotal Voting Rights
26th Jan 200912:21 pmRNSDistribution agreement in Turkey
20th Jan 20095:03 pmRNSHolding(s) in Company
15th Jan 20091:43 pmRNSIssue of Equity
6th Jan 20093:23 pmRNSResults of General Meeting
5th Jan 20094:41 pmRNSIssue of Equity
31st Dec 20087:00 amRNSTotal Voting Rights
19th Dec 20084:22 pmRNSHolding(s) in Company
12th Dec 200810:47 amRNSNotice of EGM
9th Dec 20084:30 pmRNSIssue of Equity
8th Dec 200811:15 amRNSA Book on Zolpidem Effects Published
4th Dec 200810:13 amRNSFull Colostrinin Study Results published
28th Nov 20084:24 pmRNSTotal Voting Rights
26th Nov 20087:00 amRNSColostrinin Test marketing in Poland
25th Nov 20083:39 pmRNSIssue of Equity
24th Nov 20087:00 amRNSFocus on Colostrinin revenue generation
10th Nov 20087:00 amRNSIssue of Shares
4th Nov 20081:10 pmRNSShareholding
31st Oct 200810:56 amRNSTotal Voting Rights
27th Oct 20087:00 amRNSIssue of Equity
13th Oct 20085:19 pmRNSSignificant Shareholding
9th Oct 20083:59 pmRNSHolding(s) in Company
9th Oct 20087:00 amRNSEuropean Launch of Colostrinin in Cyprus
6th Oct 200812:51 pmRNSGeneral Meeting, Share Capital Sub-division
6th Oct 20087:00 amRNSZolpidem Review
2nd Oct 20082:03 pmRNSSignificant Shareholding
30th Sep 20083:44 pmRNSTotal Voting Rights
23rd Sep 20085:29 pmRNSHolding(s) in Company
23rd Sep 20085:21 pmRNSHolding(s) in Company
23rd Sep 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSIssue of Equity
12th Sep 20087:00 amRNSGeneral Meeting
2nd Sep 20084:07 pmRNSTR-1 announcement
29th Aug 200812:33 pmRNSTotal Voting Rights
13th Aug 20087:00 amRNSPlacing
12th Aug 20087:00 amRNSFinancing and Commercial Upda

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.